Lymphoma research presented at ASCO 2025 highlighted investigational treatments for FL, HL, and DLBCL as well as a revised staging system for NKTCL.

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which ...